Why Maze Therapeutics, Inc.’s (MAZE) Stock Is Up 7.47%
As of Tuesday, October 20, Maze Therapeutics, Inc.’s MAZE share price has surged by 7.47%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Commentary & Analysis
Why Maze Therapeutics, Inc.’s (MAZE) Stock Is Up 6.52%
As of Monday, October 19, Maze Therapeutics, Inc.’s MAZE share price has surged by 6.52%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Maze Therapeutics, Inc.’s (MAZE) Stock Is Up 5.42%
As of Monday, October 12, Maze Therapeutics, Inc.’s MAZE share price has surged by 5.42%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Maze Therapeutics, Inc.’s (MAZE) Stock Is Up 5.22%
As of Monday, September 28, Maze Therapeutics, Inc.’s MAZE share price has surged by 5.22%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Maze Therapeutics, Inc.’s (MAZE) Stock Is Up 28.25%
As of Tuesday, September 22, Maze Therapeutics, Inc.’s MAZE share price has surged by 28.25%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | MAZE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,637.9 | $469.8 | 52% |
|
| Shares Out (Mil) | 59.0 | 43.5 | 51% |
|
| Institutional Ownership | 98.9% | 81.2% | 83% |
|
| Float (Mil) | 36.8 | 46.7 | 40% |
|
| Beta | na | 0.73 | na |
|
| Avg Daily Volume (000s) | 656 | 265 | 63% |
|
| Price Change (52-week) |
(8.6%) | 54.3% | 43% |
|
| Growth | MAZE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | na | (2.4%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 10 | 10 | |
| Current EPS | ($0.752) | ($2.725) | ($3.187) | |
| Month Ago EPS | ($0.760) | ($2.759) | ($3.298) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.749) | ($2.671) | ($3.189) | |
| Year/Year Chg | (1.1%) | (10.7%) | 18.6% | |
| Financials | MAZE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $20 | $326 | 13% |
|
| Net Income (TTM) (Mil) | ($134) | ($11) | 9% |
|
| EPS (TTM) | ($2.517) | ($0.700) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($107) | ($6) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($62) | $3 | 18% |
|
| Long-Term Debt (Q1) (Mil) | $56 | $6 | 40% |
|
| Enterprise Value (Q1) (Mil) | $1,288 | $493 | 44% |
|
| Valuation | MAZE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.72 | 2.16 | 74% |
|
| P/E | na | 17.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.3 | na |
|
| Ratios | MAZE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 69.4% | 96% |
|
| Net Margin | (668.0%) | 3.4% | 1% |
|
| ROA | (32.0%) | (22.0%) | 16% |
|
| ROE | (37.3%) | (20.6%) | 18% |
|
| Liabilities to Assets | 14.8% | 31.5% | 9% |
|
| F-Score | 3 | 3 | 18% |
|
Maze Therapeutics, Inc. did not pass any screens on 11/2/2026.
